This story contains spoilers from Season 5, Volume 2 of “Stranger Things, now streaming on Netflix. After four-and-a-half ...

With its profanity-laced script, Lucas Hnath’s Molière adaptation, starring Matthew Broderick, is a mischievous clash of the ...

The First Shadow" is a prequel that focuses on Henry Creel, aka Vecna. That backstory might be a clue to his fate in the ...

Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...

He reckons his latest game, The Hundred Line: Last Defense Academy might indeed be the last defense against the rising tide of machine-based creations. "At this rate, Hundred Line might truly become ...

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...

Daiichi Sankyo begins patient dosing in DESTINY-Endometrial02 phase 3 trial of Enhertu in patients with HER2 expressing endometrial cancer: Tokyo Tuesday, December 23, 2025, 10:00 ...

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

The FDA has granted breakthrough therapy designation (BTD) to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the ...

Forty-one years after teenagers Shelly Colliflower and Vincent Tijerina were killed near Lake Weatherford, the questions ...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer ...

Cambridge: AstraZeneca and Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with ...